爱美客技术发展股份有限公司 防范大股东及关联方资金占用专项制度 爱美客技术发展股份有限公司 防范大股东及关联方资金占用专项制度 第一章 总 则 第一条 为了建立防止控股股东及其关联方占用爱美客技术发展股份有限公 司（以下简称"本公司"或"公司"）资金的长效机制，杜绝控股股东及其关联 方占用资金行为的发生，根据《中华人民共和国公司法》《中华人民共和国证券 法》 《上市公司监管指引第 8 号——上市公司资金往来、对外担保的监管要求》 《深圳证券交易所创业板股票上市规则》等法律、法规及规范性文件及《爱美客 技术发展股份有限公司章程》（以下简称《公司章程》）的相关规定，结合公司实 际情况，制定本制度。 第二条 本制度适用于公司及纳入公司合并会计报表范围的子公司与公司控 股股东及其关联方之间的资金往来管理。 第三条 公司董事、高级管理人员对维护公司资金安全负有法定义务。 第四条 占用资金包括经营性占用资金和非经营性占用资金。 经营性占用资金是指控股股东及其关联方通过采购、销售等生产经营环节的 关联交易产生的占用资金。 非经营性占用资金是指为控股股东及其关联方垫付工资、福利、保险、广告 等费用和其他支出，代控股股东及其关 ...

Core Viewpoint - The medical beauty sector experienced a slight increase of 0.81% on October 31, with Jinbo Biological leading the gains, while the overall market indices saw declines [1]. Group 1: Market Performance - On October 31, the Shanghai Composite Index closed at 3954.79, down 0.81%, and the Shenzhen Component Index closed at 13378.21, down 1.14% [1]. - Jinbo Biological's stock price rose by 2.35% to 251.28, with a trading volume of 16,800 hands and a transaction value of 421 million yuan [1]. - Other notable stocks in the medical beauty sector included *ST Meigu, which increased by 1.42% to 3.58, and Huaxi Biological, which rose by 0.82% to 66.65 [1]. Group 2: Capital Flow - The medical beauty sector saw a net inflow of 5.8151 million yuan from institutional investors, while retail investors experienced a net outflow of 7.1663 million yuan [2]. - The sector also recorded a net inflow of 1.3512 million yuan from speculative funds [2].

Key Insights - The report highlights significant changes in fund allocation during Q3 2025, with a notable increase in equity positions and a shift towards AI and new energy sectors, while consumer sectors faced reductions [8][9][10] - The performance of various industries shows a mixed trend, with coal and machinery sectors experiencing fluctuations in revenue and profit margins, while technology and communication sectors demonstrate robust growth [24][26][29][35][40] Fund Allocation Insights - Fund sizes increased significantly, with a 20% rise in active fund products, driven by a strong A-share market performance, particularly a 20% increase in the CSI 800 index [8] - There is a reinforced trend of reducing mainboard allocations while increasing investments in emerging sectors, with the STAR Market allocations reaching new highs [9] - AI and new energy sectors are leading the allocation trends, while consumer sectors like home appliances and automobiles are seeing widespread reductions [9][10] Industry Performance Insights - The coal industry is facing challenges, with companies like Pingmei and Lu'an reporting significant declines in revenue and profit due to structural changes in sales, although Q4 is expected to see recovery due to rising coal prices [35][44] - The machinery sector, represented by companies like Rongzhi Rixin, is experiencing substantial growth, with a 13.9% increase in revenue and an impressive 890% rise in net profit year-on-year [26] - The communication sector, particularly companies like New Yisheng, reported a 152.5% year-on-year revenue increase, driven by strong demand for optical communication products [24] Company-Specific Insights - Bull Group's revenue decline is narrowing, with healthy cash flow, and the company is expected to maintain a "buy" rating based on future profit projections [20] - Hikvision is showing signs of recovery with stable profits and cash flow, supported by advancements in AI technology [47] - Huabao New Energy is facing short-term profit pressure due to tariffs but maintains strong growth potential with a projected increase in net profit over the next few years [29]

Group 1: Changshu Bank (601128.SH) - The bank reported a revenue of 9.05 billion with a year-on-year growth of 8.2% and a net profit attributable to shareholders of 3.36 billion, up 12.8% year-on-year [4] - The weighted average return on equity (ROAE) was 15.02%, an increase of 0.06 percentage points year-on-year [4] - The net interest margin decline has narrowed quarter-on-quarter, indicating effective cost control, while the non-performing loan ratio remains low, showcasing strong risk compensation ability [4] Group 2: Sinopec (600028.SH/0386.HK) - For the first three quarters of 2025, Sinopec achieved total operating revenue of 2.1134 trillion, a decrease of 10.7% year-on-year, and a net profit of 30 billion, down 32.2% year-on-year [5] - In Q3 2025, the company reported an operating revenue of 704.4 billion, a year-on-year decline of 10.9% but a quarter-on-quarter increase of 4.6%, with a net profit of 8.5 billion, down 0.5% year-on-year and up 3.4% quarter-on-quarter [5] Group 3: Deep City Transportation (301091.SZ) - The company reported revenues of 670 million and a net profit of 40 million for the first three quarters of 2025, reflecting a year-on-year decline of 14.0% and 27.2% respectively [5] - In Q3 2025, the company achieved revenues of 260 million and a net profit of 50 million, with year-on-year declines of 18.9% and 23.8% respectively [5] Group 4: Reading Group (0772.HK) - The company is increasing its investment in comic adaptations, with a focus on the progress of new series being launched [6][7] Group 5: Aimeike (300896.SZ) - For the first three quarters of 2025, Aimeike reported revenues of 1.86 billion, down 21.5% year-on-year, and a net profit of 1.09 billion, down 31.0% year-on-year [8] - The quarterly revenues for Q1, Q2, and Q3 of 2025 were 660 million, 640 million, and 570 million respectively, with year-on-year declines of 17.9%, 25.1%, and 21.3% [8] Group 6: Huali Group (300979.SZ) - The company reported revenues of 18.68 billion for the first three quarters of 2025, a year-on-year increase of 6.7%, while the net profit decreased by 14.3% to 2.44 billion [10] - The basic earnings per share (EPS) was reported at 2.09 yuan [10] Group 7: Liangpinpuzi (603719.SH) - For the first three quarters of 2025, the company achieved revenues of 4.14 billion, down 24.45% year-on-year, and reported a net loss of 122 million, compared to a profit of 19 million in the same period last year [11] - In Q3 2025, the company reported revenues of 1.311 billion, down 17.72% year-on-year, with a net loss of 29 million, compared to a loss of 4.5 million in the same quarter last year [11]

Core Viewpoint - The company's performance in Q3 2025 continues to show weakness, primarily due to ongoing macroeconomic consumption demand issues and significant market competition pressures in the "Hi-Body" and regenerative product segments [5]. Financial Performance - For the first three quarters of 2025, the company reported revenue of 1.86 billion, a year-on-year decline of 21.5%, and a net profit attributable to shareholders of 1.09 billion, down 31.0% [4]. - Q1, Q2, and Q3 2025 revenues were 660 million, 640 million, and 570 million respectively, reflecting year-on-year declines of 17.9%, 25.1%, and 21.3%. Net profits for the same quarters were 440 million, 350 million, and 300 million, with year-on-year declines of 15.9%, 41.7%, and 34.6% [4]. Profitability Metrics - The gross margin for the first three quarters of 2025 decreased by 1.4 percentage points to 93.4%, while the net profit margin attributable to shareholders fell by 8.1 percentage points to 58.6%. In Q3 2025, the gross margin was 93.2%, down 1.4 percentage points year-on-year, and the net profit margin was 53.7%, down 11.0 percentage points [6]. - The decline in gross margin is attributed to a lower proportion of high-priced product sales and increased competition from new compliant products in the market [6]. Expense Analysis - The company's expense ratio for the first three quarters of 2025 increased by 12.5 percentage points to 31.8%. The breakdown includes sales, management, R&D, and financial expense ratios of 12.4%, 6.4%, 12.7%, and 0.3%, respectively, with year-on-year increases of 3.7, 2.5, 4.8, and 1.4 percentage points [7]. - In Q3 2025, the expense ratio rose to 38.6%, up 18.2 percentage points year-on-year, with sales, management, R&D, and financial expense ratios at 15.4%, 8.8%, 14.3%, and 0.1%, respectively [7]. Taxation Impact - The company paid 23.3 million in taxes and additional fees for the first three quarters of 2025, reflecting a year-on-year increase of 59.1% due to higher value-added tax payments [8]. Product Development and Market Expansion - The company is progressively enhancing its aesthetic medical product lineup, having launched a new bone filler product "Kola" and completed the acquisition of REGEN Biotech, Inc. to enrich its regenerative product matrix [9]. - The company is also advancing its pipeline for botulinum toxin and semaglutide injection products, and has entered the hair medical market with the registration of minoxidil lotion [9]. - In October, the company completed the filing of a new cosmetic raw material "Glycyrrhizin A," aiming to penetrate the "medical-grade skincare" sector, with expectations for "pharmaceutical-cosmetic synergy" to create new growth avenues [9].

Group 1 - The company reported Q3 2025 performance, meeting market expectations with improvements compared to Q2 2025. Revenue for the first three quarters of 2025 was 1.865 billion yuan, down 21.49% year-on-year, while net profit attributable to shareholders was 1.093 billion yuan, down 31.05% year-on-year [1] - In Q3 2025, the company achieved a single-quarter revenue of 566 million yuan, down 21.27% year-on-year, and a net profit of 304 million yuan, down 34.61% year-on-year [1] - The increase in sales expense ratio significantly impacted profitability, with Q3 2025 gross margin at 93.19% (down 1.36 percentage points year-on-year) and net margin at 55.88% (down 8.66 percentage points year-on-year) [1] Group 2 - The company is expanding its product matrix through acquisitions, enhancing efficiency through industrial synergy. A wholly-owned subsidiary received approval for minoxidil lotion, a first-line topical treatment for androgenetic alopecia and alopecia areata, covering the entire population with 2% and 5% specifications [2] - The company acquired 85% of South Korean REGEN for 190 million USD, with core products AestheFill and PowerFill approved in 35 and 23 countries respectively, creating synergy with existing products [2] - The company is increasing R&D investment, with a robust pipeline. New products include the chin filler "Gekela" launched in May, and ongoing projects such as injectable botulinum toxin in the registration phase and clinical trials for semaglutide injection and deoxycholic acid injection [2] Group 3 - The company is deeply engaged in the domestic medical aesthetics market, with strong barriers to entry and a solid core product matrix. Despite short-term performance fluctuations, the potential for new product launches and synergy with REGEN is promising [3] - Revenue forecasts for 2025-2027 have been adjusted to 2.53 billion, 2.91 billion, and 3.51 billion yuan respectively, with corresponding net profit forecasts of 1.46 billion, 1.74 billion, and 2.18 billion yuan [3] - The company maintains a "buy" rating despite the adjustments, with expected PE ratios of 33, 28, and 22 times for 2025-2027 [3]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Insights - The company reported Q3 2025 earnings that met market expectations, showing improvements compared to Q2 2025. For the first three quarters of 2025, revenue was 1.865 billion yuan, down 21.49% year-on-year, and net profit attributable to the parent company was 1.093 billion yuan, down 31.05% year-on-year. In Q3 2025 alone, revenue was 566 million yuan, down 21.27% year-on-year, and net profit was 304 million yuan, down 34.61% year-on-year [7] - The company is expanding its product categories through acquisitions and enhancing operational efficiency. It has entered the hair health sector with the approval of minoxidil topical solution and acquired 85% of South Korean REGEN for $190 million, which will synergize with existing products [7] - The company is increasing R&D investments and has a robust pipeline of new products, including a chin filler launched in May and several products in clinical trials [7] - Despite short-term earnings fluctuations, the company is expected to regain growth driven by new product launches and synergies from acquisitions [7] Financial Summary - Total revenue for 2025 is estimated at 2.533 billion yuan, with a year-on-year decline of 16.3%. Net profit is projected at 1.464 billion yuan, down 25.2% year-on-year. The company expects to recover with revenue estimates of 2.911 billion yuan in 2026 and 3.513 billion yuan in 2027 [6][9] - The gross margin for Q3 2025 was 93.19%, a decrease of 1.36 percentage points year-on-year, while the net profit margin was 55.88%, down 8.66 percentage points year-on-year [7]

Core Insights - The medical beauty sector experienced a decline of 0.81% on October 30, with Jinbo Biological leading the drop at 7.07% [1] - The Shanghai Composite Index closed at 3986.9, down 0.73%, while the Shenzhen Component Index closed at 13532.13, down 1.16% [1] Medical Beauty Sector Performance - Huaxi Biological closed at 53.55, down 0.70%, with a trading volume of 30,900 shares and a transaction value of 166 million [1] - *ST Meigu closed at 3.53, down 0.84%, with a trading volume of 71,000 shares and a transaction value of 25.09 million [1] - Aimeike closed at 158.89, down 0.89%, with a trading volume of 30,100 shares and a transaction value of 47.9 million [1] - Jinbo Biological closed at 245.50, down 7.07%, with a trading volume of 29,300 shares and a transaction value of 733 million [1] Capital Flow Analysis - The medical beauty sector saw a net outflow of 2.1553 million from main funds, while retail funds experienced a net outflow of 3.2717 million [1] - Speculative funds had a net inflow of 5.4269 million [1] Individual Stock Capital Flow - Aimeike had a net outflow of 15.355 million, down 3.21%, with a net inflow of 21.139 million, down 0.44% [2] - *ST Meigu experienced a net outflow of 5.6326 million, down 22.45%, with a net inflow of 4.3275 million, up 17.25% [2] - Huaxi Biological had a net outflow of 13.9915 million, down 8.41%, with a net inflow of 16.4544 million, up 9.89% [2]

Core Insights - The company reported a revenue of 1.86 billion yuan for the first three quarters of 2025, a year-on-year decrease of 21.5%, and a net profit attributable to shareholders of 1.09 billion yuan, down 31.1% year-on-year [1] - The decline in performance is attributed to industry growth slowdown and intensified competition [1] Financial Performance - Q3 revenue was 570 million yuan, a year-on-year decline of 21.3%, with a net profit of 300 million yuan, down 34.6% year-on-year [1] - The gross margin in Q3 decreased by 1.4 percentage points to 93.2%, while the sales expense ratio increased by 6.4 percentage points to 15.4% [2] - The net profit margin and non-GAAP net profit margin in Q3 fell by 11.0 and 16.5 percentage points to 53.7% and 45.0%, respectively [2] Industry Trends - Industry growth is under pressure due to intensified competition, although the revenue decline in Q3 showed a narrowing compared to Q2 [2] - The company is actively adjusting its sales team and strategies to enhance education for doctors and institutions, aiming for improvement in future performance [2] Product Pipeline and International Expansion - The company has received approval for Minoxidil lotion and has several products at various stages of development, including Lidocaine and Dexamethasone cream, which are under review [3] - The ongoing integration of Regen and global channel expansion is expected to support the company's long-term growth in the global aesthetic medicine market [3] Profit Forecast and Valuation - The profit forecast for 2025-2026 has been revised down by 11% and 5% to 1.65 billion and 1.92 billion yuan, respectively [4] - The current stock price corresponds to a P/E ratio of 29x for 2025 and 25x for 2026, with a target price of 221 yuan, indicating a potential upside of 38% [4]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company's revenue continues to be under pressure due to macroeconomic factors, with a need for a demand turning point to emerge [5] - The company reported a revenue of 1.86 billion yuan for the first three quarters of 2025, a year-on-year decline of 21.5%, and a net profit of 1.09 billion yuan, down 31.0% year-on-year [4][5] - The gross margin slightly decreased to 93.4% for the first three quarters of 2025, while the net profit margin fell to 58.6% [5] - Increased competition in the market, particularly for high-priced products, has contributed to the decline in revenue and profit margins [5][6] - The company is expanding its product lineup in the medical beauty sector, which may provide new growth opportunities in the future [7][8] Summary by Sections Financial Performance - For Q3 2025, the company reported revenues of 570 million yuan, a decline of 21.3% year-on-year, and a net profit of 300 million yuan, down 34.6% year-on-year [4][5] - The gross margin for Q3 2025 was 93.2%, down 1.4 percentage points year-on-year, while the net profit margin was 53.7%, down 11.0 percentage points year-on-year [5] - The company's expense ratio increased by 12.5 percentage points to 31.8% for the first three quarters of 2025, with significant increases in sales, management, and R&D expenses [6] Market Position and Strategy - The company is enhancing its product offerings in the medical beauty sector, including the launch of new products and acquisitions to strengthen its market position [7] - The introduction of new products and the expansion into overseas markets are expected to drive future growth [8] Earnings Forecast - The net profit forecasts for 2025-2027 have been revised down to 1.39 billion, 1.53 billion, and 1.70 billion yuan, respectively, reflecting a decrease of 15% to 16% [8] - The report projects earnings per share (EPS) of 4.58 yuan for 2025, with corresponding price-to-earnings (P/E) ratios of 36, 32, and 29 for the years 2025, 2026, and 2027 [8][9]